Diligence memo · auto-generated · as of July 3, 2026
Gladius Therapeutics, Inc.
Gladius Therapeutics, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Gladius Therapeutics, Inc. operates in Pharma, based in PHILADELPHIA.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Gladius Therapeutics, Inc. has raised $300K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $300K on 2023-08-14.
Most recent recorded round closed around 2023-08-14.
Valuation (modeled)modeled
Provath models Gladius Therapeutics, Inc. at approximately $2.3M (range $168K–$10M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.96× the median modeled value of Pre-Seed Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era. Within the normal band (96% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.9 yr ago; this sector typically re-raises about every 16 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 24% of Pharma peers (310 compared).
Modeled value ranks above 23% of those peers.
Closest niche peers: Acanna Therapeutics, Inc., Neural Therapeutics Inc., Insignis Therapeutics Inc., Atacama Therapeutics, Inc., Pharma Acuity, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.